Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors

被引:46
|
作者
Wang, Difei [1 ]
机构
[1] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA
关键词
SMALL-MOLECULE INHIBITOR; 2 CATALYTIC DOMAINS; CRYSTAL-STRUCTURE; ZINC-BINDING; STRUCTURAL BASIS; HDAC INHIBITORS; BIOLOGICAL EVALUATION; PROTEIN DEACETYLASE; SUBSTRATE-BINDING; HYDROXAMIC ACIDS;
D O I
10.2174/156802609788085287
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The catalytic activity of the histone deacetylase ( HDAC) enzymes is directly relevant to the pathogenesis of cancer as well as several other diseases. HDAC inhibitors have been shown to have the potential to treat several types of cancers. The role of computational study of the HDAC enzymes is reviewed, with particular emphasis on the important role of molecular modeling to the development of HDAC inhibitors with improved efficacy and selectivity. The use of two computational approaches - one structure-based, and the second ligand-based - toward inhibitors against the different HDAC sub-classes, are summarized.
引用
收藏
页码:241 / 256
页数:16
相关论文
共 50 条
  • [1] Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
    Phimmachanh, Monica
    Han, Jeremy Z. R.
    O'Donnell, Yolande E., I
    Latham, Sharissa L.
    Croucher, David R.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [2] Strategies To Design Selective Histone Deacetylase Inhibitors
    Melesina, Jelena
    Simoben, Conrad V.
    Praetorius, Lucas
    Bulbul, Emre F.
    Robaa, Dina
    Sippl, Wolfgang
    [J]. CHEMMEDCHEM, 2021, 16 (09) : 1336 - 1359
  • [3] Selective Histone Deacetylase Inhibitors
    Pan, Huili
    Cao, Jiangying
    Xu, Wenfang
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (03) : 247 - 270
  • [4] Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    [J]. ADVANCED BIOMEDICAL RESEARCH, 2019, 8 (01):
  • [5] Novel and Selective Inhibitors of Histone Deacetylase
    Rosse, Gerard
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (11): : 879 - 880
  • [6] Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore
    Melesina, Jelena
    Praetorius, Lucas
    Simoben, Conrad V.
    Robaa, Dina
    Sippl, Wolfgang
    [J]. FUTURE MEDICINAL CHEMISTRY, 2018, 10 (13) : 1537 - 1540
  • [7] Toward selective histone deacetylase inhibitor design: Homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases
    Wang, DF
    Helquist, P
    Wiech, NL
    Wiest, O
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) : 6936 - 6947
  • [8] Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases
    Wang, Yunfei
    Stowe, Ryan L.
    Pinello, Christie E.
    Tian, Guimei
    Madoux, Franck
    Li, Dawei
    Zhao, Lisa Y.
    Li, Jian-Liang
    Wang, Yuren
    Wang, Yuan
    Ma, Haiching
    Hodder, Peter
    Roush, William R.
    Liao, Daiqing
    [J]. CHEMISTRY & BIOLOGY, 2015, 22 (02): : 273 - 284
  • [9] Design of novel histone deacetylase inhibitors
    Siliphaivanh, Phieng
    Harrington, Paul
    Wittera, David J.
    Ottea, Karin
    Tempest, Paul
    Kattar, Sam
    Kral, Astrid M.
    Fleming, Judith C.
    Deshmukh, Sujal V.
    Harsch, Andreas
    Secrist, Paul J.
    Miller, Thomas A.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (16) : 4619 - 4624
  • [10] Clinical Studies of Histone Deacetylase Inhibitors
    Prince, H. Miles
    Bishton, Mark J.
    Harrison, Simon J.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (12) : 3958 - 3969